[Biojava-l] Microfluidics: Second Generation Technologies Driving Commercial Applications

[support at biotaq.com]

********************************************************
to unsubscribe, simply reply to this email, thanks.
********************************************************

New Report from D&MD Publications
Microfluidics: Second Generation Technologies Driving Commercial
Applications

Westborough, MA, April 24, 2003 - Microfluidic product revenues are
forecasted to grow by more than 50% per year through 2007, according to a
new Report released today from D&MD Publications.

The direction of Microfluidics, a group of technologies stemming from both
microelectronics and bioanalytical chemistry, is evolving. Changes in the
funding environment and a decade of commercial experience has guided
technology providers towards a more realistic niche market approach as
opposed to the mass production vision of the early nineties. Microfluidics
companies appear to have finally achieved an appropriate sense of
direction.

D&MD's Microfluidics Market Analysis Report thoroughly analyzes the
evolution of commercial microfluidics with emphasis on the forces driving
recent shifts in company strategies and approaches to the market.  These
strategy shifts have presented a wide array of application areas, which
are described in-depth, including relevant predictions for future revenue
potential.  In addition, this Report discusses the current focuses on
business aspects of microfluidics, including the competitive environment,
business models employed by market participants, and a thorough market
analysis with revenue estimates and projections for the field as a whole
and the most commercially viable segments.

Microfluidics continues to face a bright future. It is finding commercial
success as value-added components of many systems such as mass
spectrometry, nucleic acid assays, ion channel targets and high-content
screening, instead of one in which the technologies themselves take center
stage.

Learn more about Microfluidics: Second Generation Technologies Driving
Commercial Applications at

http://www.drugandmarket.com/9115?source=9115btq

For further information, or to purchase this Report, contact Renée Marks
of D&MD at +1 (508) 616-5566 (phone), +1 (508) 616-5544 (fax), One
Research Drive, P.O. Box 5194, Westborough, MA 01581-5194 USA, at
cust.serv at drugandmarket.com, or at
www.drugandmarket.com/9115?source=9115btq
--------------------------------------------------------------------------
-----------------------------------
For nearly two decades, D&MD Publications has been the leading provider of
quality market analysis, opportunity assessment, and tactical
guidance-filling the ever-changing needs of the life sciences market.

D&MD Publications is part of the Informa Group plc-the leading provider of
scientific, technological, and business information to the global life
science community. Other members include BioTechniques, IBC Life Sciences
Conferences, BioProcess International, and Preclinica. Learn more at
www.lifesciencesinfo.com.


------------------------------
********************************************************
This segmented email list tends to serve the people who are
interested in news and product info in drug discovery sector. To
unsubscribe, simply reply to this email.

To distribute your releases to this list, contact sales at biotaq.com.

To order market report "Cancer Immunotherapy Beyond Monoclonals"
from Biotaq.com at:

http://www.biotaq.com/onsale/biotaqreports.htm

BIOTAQ.COM's email Newswire service is focused exclusively on biotech
industry. Edit or change your interest category selections at:

https://www.biotaq.com/interests.htm
**************************************************************************
**